Bioceres Crop Solutions (BIOX) Q4 2024 earnings summary

Executive summary

• Fiscal year 2024 revenues grew 11% year-over-year to $464.8 million, with Q4 revenues up 18% to $124.0 million, driven by HB4 sales and favorable conditions in key markets.

• Adjusted EBITDA for FY24 was $81.4 million, maintaining last year's record high, while GAAP net income declined to $6.2 million from $20.2 million in FY23.

• HB4 Wheat received U.S. regulatory approval, expanding the addressable market and validating the technology in new geographies.

• Management transitions and new leadership appointments in biologicals and Brazil operations were completed to drive growth and innovation.

• Despite challenging agricultural markets and declining crop prices, the company maintained resilience and profitability through a diversified portfolio.

Financial highlights

• Q4 revenues reached $124 million, up 18% year-over-year; full-year revenues were $464.8 million, up 11% from fiscal 2023.

• FY24 gross profit was $186.6 million, with a gross margin of 40%; Q4 gross profit was $47.4 million, gross margin 38%.

• Adjusted EBITDA for FY24 was $81.4 million; Q4 adjusted EBITDA nearly doubled to $19.9 million.

• Net debt-to-LTM Adjusted EBITDA ratio increased to 2.51x due to higher working capital and debt.

• FY24 GAAP net income was $6.2 million, down from $20.2 million in FY23.

Outlook and guidance

• Focus for FY25 includes profit expansion, improved cash generation, and scaling HB4 and HB4 Soy through strategic partnerships.

• Continued investment in biocontrol solutions, with anticipated approvals in the U.S., Europe, and Brazil to drive growth.

• Ramping up new manufacturing capacity in Brazil and Pergamino is a priority.

• Management expects FY24 results to serve as a foundation for future growth and profitability.